In Africa, pregnant women and young children are the most vulnerable to malaria.
However, malaria control interventions and strategies have achivied important results in the last years.
COVID-19 has now made these interventions critical, and could undo the results obtained so far, as highlighted by scientists in the Lancet: https://bit.ly/2Tfyxwn.
Potentially, COVID-19 could indirectly cause more deaths than it already does directly, in the context of Africa’s weak and fragile health systems.
An international research team has begun patient enrollment in a clinical trial testing multiple investigational Ebola therapies in the Democratic Republic of the Congo (DRC). The randomized, controlled trial is
Ebola vaccine candidates are currently being evaluated in phase I–III clinical trials conducted in Africa, the EU and the US. Although preclinical development of candidate vaccines utilise different platforms, including
